top of page
PleoPharma, Inc. Closes $36 Million Series B Financing Round
Phoenixville, pa, October 21, 2025 – PleoPharma, Inc., a privately held company focused on finding treatments for cannabis-related health issues, announced today the closing of a $36MM Series B financing round.
PleoPharma, Inc.
Oct 20
PLEOPHARMA, INC. Presents Positive Cannabis Withdrawal Clinical Trial Results at The College on Problems of Drug Dependence Annual Meeting
PleoPharma, Inc., a privately held company focused on cannabis-related health issues, announced today, the presentation of data from their Phase 2b multicenter, randomized, double-blind, multi-dose, placebo-controlled clinical trial of titrating doses of PP-01 for the mitigation of Cannabis Withdrawal Syndrome (CWS) in participants with Cannabis Use Disorder (CUD) at the 2025 annual meeting of The College on Problems of Drug Dependence in New Orleans, LA.
PleoPharma, Inc.
Jun 18
PLEOPHARMA, INC. Reports New Patent Issuance
New Patent Issued on April 8, 2025 Patent Protection to March 2041 PHOENIXVILLE, Pa., April 16, 2025 /PRNewswire/ -- PleoPharma, Inc....
PleoPharma, Inc.
Apr 15
FDA GRANTS FAST TRACK DESIGNATION TO PLEOPHARMA, INC's INVESTIGATIONAL NEW DRUG, PP-01, FOR THE MITIGATION OF CANNABIS WITHDRAWAL SYMPTOMS IN PATIENTS WITH CANNABIS USE DISORDER:
A POTENTIAL FIRST IN TREATMENT Fast Track Designation highlights the potential of PP-01 to address a serious and unmet need for patients...
PleoPharma, Inc.
Feb 13
bottom of page